TG Therapeutics: Concerns About Slowing Growth And New Competition
TG Therapeutics continues strong execution with Briumvi, maintaining beat-and-raise performance and robust financials, including a new $100 million buyback program. However, high investor expectations, slowing growth of Briumvi and concerns about increased competition in the multiple sclerosis market have weighted on its share price. Novartis is testing a less frequently administered version of Kesimpta and Roche's fenebrutinib has generated positive phase 3 results in relapsing multiple sclerosis.
TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing
TGTX has seen rapid enrolment of the ENHANCE study which could allow a simplified dosing regime of IV Briumvi. A readout is possible for mid-2026. Investors may need to wait longer for the subcutaneous formulation of Briumvi to become available, with a readout from clinical work possible in late 2026 or early 2027. Kyverna Therapeutics's KYV-101 is emerging as a potential competitor to TGTX's Azer-cel in Multiple Sclerosis, although initial KYV-101 data is from a handful of patients.
TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised
TG Therapeutics beats third-quarter estimates as a surge in Briumvi sales drives revenues up 92.8% and leads to a higher 2025 outlook.
TG Therapeutics Q3 Earnings: Strong Quarter For Briumvi As CD20 Market Grows
TG Therapeutics, Inc. reported strong Q3 results, with Briumvi revenues up 84% year-over-year and full-year guidance raised to $585 million. TGTX continues to expand Briumvi's market presence, driven by clinical data, increased prescriber adoption, and a growing anti-CD20 MS therapy market. A subcutaneous version of Briumvi is in Phase 3 trials, potentially doubling TGTX's market opportunity if approved and launched by 2028.
TG Therapeutics, Inc. (TGTX) Q3 2025 Earnings Call Transcript
TG Therapeutics, Inc. ( TGTX ) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - Chairman, CEO & President Adam Waldman - Chief Commercialization Officer Sean Power - CFO, Corporate Secretary & Treasurer Conference Call Participants Tara Bancroft - TD Cowen, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Corinne Jenkins - Goldman Sachs Group, Inc., Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Emily Bodnar - H.C. Wainwright & Co, LLC, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division William Wood - B.
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line
TG Therapeutics slides 18% as second-quarter earnings fall short despite a 92% revenue jump fueled by surging Briumvi sales.
TG Therapeutics, Inc. (TGTX) Q2 2025 Earnings Call Transcript
TG Therapeutics, Inc. (NASDAQ:TGTX ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Adam Waldman - Chief Commercialization Officer Jenna Bosco - Senior Vice President of Corporate Communications Michael S. Weiss - Chairman, CEO & President Sean A.
TG Therapeutics (TGTX) Misses Q2 Earnings Estimates
TG Therapeutics (TGTX) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.04 per share a year ago.
TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 Release
TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics: Another Possible Avenue Of MS Growth With Azer-Cel
TG Therapeutics, Inc.'s BRIUMVI saw Q1 2025 revenue surge 137% YoY to $119.7M, driven by strong U.S. growth. A subcutaneous version of TGTX's BRIUMVI is in phase 1 trials, with late-stage development planned for 2025, aiming to broaden patient reach and administration options. Azer-cel, an allogeneic off-the-shelf CD19 CAR-T, is in phase 1 for progressive MS, targeting a new MS market segment beyond relapsing MS.
TG Therapeutics: Estimates Could Soon Be Raised Again
TG Therapeutics remains on track, with Q1 revenue matching my model and potential for 110% growth in 2025 if price increases hold. Analyst estimates for 2025 revenue have risen sharply, and Q2 expectations now exceed both company guidance and my own projections. Recent price increases for Briumvi and pipeline catalysts like a subcutaneous version could drive further outperformance versus current expectations.
TG Therapeutics, Inc. (TGTX) Q1 2025 Earnings Call Transcript
TG Therapeutics, Inc. (NASDAQ:TGTX ) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants Jenna Bosco - Chief Communications Officer Michael Weiss - Chairman and Chief Executive Officer Adam Waldman - Chief Commercialization Officer Sean Power - Chief Financial Officer Conference Call Participants Tara Bancroft - TD Cowen Michael DiFiore - Evercore ISI Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Prakhar Agrawal - Cantor Fitzgerald Operator Greetings, and welcome to TG Therapeutics First Quarter Conference Call and Webcast.
